Home | Site Map | Contact Us| Reference
 |
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Initiative
|
|
Why were the women in the WHI estrogen plus progestin clinical trial told to stop taking the study medication in July 2002?
An analysis by members of the independent Data Safety and Monitoring Board (DSMB) that monitors the health of participants during the study found that women taking the estrogen plus progestin combination had an increased risk of breast cancer compared to women taking placebo pills. The DSMB analysis also indicated that the overall health risks of taking estrogen plus progestin outweighed the benefits. In addition to an increased breast cancer risk, women in the estrogen plus progestin group had an increased risk of heart attacks, strokes, and blood clots in the lungs and legs.
What is the Women's Health Initiative?
What are the effects of estrogen and menopause on bone health in women?
